Treatment with Descartes-08, an investigational CAR T-cell therapy, markedly eased symptoms of myasthenia gravis (MG) in three patients participating in a Phase 1/2 clinical trial assessing the therapy’s safety and preliminary efficacy. “This is the first clinical trial of CAR T-cells for an autoimmune disease. Naturally, the first patients enrolled are some of our most severely affected […]

With its injectable biosensor technology well into the clinical development stage, Glympse Bio has its sights set on revolutionizing the way we diagnose diseases and track their progression throughout the body. Helping Glympse along its path through trials, FDA approval and beyond will be Tram Tran, M.D., who joins the Cambridge, Mass.-based company as its […]

Obsidian Therapeutics has raked in $115 million to realize the long-unfulfilled therapeutic promise of tumor-infiltrating lymphocytes (TILs). The series B gives Obsidian a shot at showing whether freeing TILs from IL-2 can finally unleash power that research has hinted at for almost 30 years. Researchers at the NIH began revealing the therapeutic potential of TILs […]